Wellbeing Digital Sciences Inc. (E:MEDI)

Business Focus: Healthcare Facilities & Services (NEC)

Get the company report for the most recent outlook updated daily

Jun 19, 2023 04:30 pm ET

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK” or the “Subsidiary”), will participate at the upcoming

Jun 16, 2023 04:30 pm ET

Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that the Company has entered into a share purchase agreement (the “Purchase Agreement”), dated June 7, 2023, with Cardinal Group Inc. (the “Purchaser”), pursuant to which it proposes to assign (the “Transaction

May 25, 2023 04:15 pm ET

Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary KGK Science Inc. (“KGK” or the “Subsidiary”) will participate at the upcoming Nutrition Industry Association (“NIA”) Spring Forum to take place on May 29 to June 1, 2023 in California.

May 03, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that a clinical study conducted by its wholly owned subsidiary KGK Science Inc. (“KGK”), has shown positive results of UP360 supplementation in helping mount a robust immune response following influenza vaccination.

Apr 18, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has begun recruiting participants, on behalf of client Nova Mentis Life Science Corp. (“Nova Mentis” or the “Client”) (CSE:NOVA, OTC:NMLSF, FRA:

Apr 11, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has received institutional review board (IRB) approval in Canada, on behalf of client Nova Mentis Life Science Corp. (“Nova Mentis” or the “Client”) (CSE:NO

Apr 06, 2023 04:15 pm ET

Wellbeing Announces Cease Trade Order

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announces that the British Columbia Securities Commission (the “BCSC”) has issued a Failure-to-File Cease Trade Order (“FFCTO”) pursuant to National Policy 11-207 – Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions dated, April 5, 2023, in respect of the securities of the Company as a result of the Company’s inability to file its:

Apr 06, 2023 09:35 am ET

IIROC Trading Halt - MEDI

TORONTO, April 6, 2023 /CNW/ - The following issues have been halted by IIROC:

Mar 16, 2023 04:30 pm ET

Wellbeing Provides Bi-Weekly Default Status Report

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) is providing this update with respect to the management cease trade order (“MCTO”) issued by the British Columbia Securities Commission (“BCSC”) on January 31, 2023, as previously announced by the Company on February 1, 2023 (the “Default Announcement”). The MCTO was issued in connection with the filing of the Company’s audited annual financial statements for the year ended October 31, 2022, and the related management’s discussion and analys

Mar 16, 2023 08:30 am ET

Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at the upcoming Benzinga Psychedelic Capital Conference taking place on April 13th, 2023 in Miami Florida.

Mar 13, 2023 08:30 am ET

Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate virtually at the upcoming Cantor Fitzgerald Psychedelic Clinics panel discussion on March 15, 2023.

Mar 09, 2023 08:30 am ET

Wellbeing Digital to Participate in The Global Biomedical Design Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Andrew Charrette, Director Regulatory Affairs and Psychedelic Advisor from the Company's wholly owned subsidiary KGK Sciences Inc. (“KGK” or the “Subsidiary”), will participate virtually at the upcoming Global Biomedical Design Confere

Mar 08, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout

Mar 02, 2023 04:30 pm ET

Wellbeing Provides Bi-Weekly Default Status Report

Mar 01, 2023 08:30 am ET

Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ MarigoldLIVE International Women’s Day Networking Virtual Event taking place on March 8th, 2023.

Feb 16, 2023 05:32 pm ET

Wellbeing Provides Bi-Weekly Default Status Report

Feb 15, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed preclinical safety studies for Rarebird Coffee (“Rarebird”), a manufacturer and own label distributor of coffee crafted with paraxanthine (Px), a caffeine replacemen

Feb 14, 2023 08:30 am ET

Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has received an exemption under Section 56 of the Controlled Drugs and Substances Act, on behalf of client Nova Mentis Life Science Corp. (“Nova Mentis” or the “Cl

Feb 01, 2023 08:31 am ET

Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces today that as a result of delays to its audit, the Company’s annual financial statements and accompanying management's discussion and analysis for the fiscal year ended October 31, 2022 (the “Annual Filings”) were not finalized by Ja

Jan 25, 2023 08:30 am ET

Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate at the upcoming Psychedelic Medicine Association (PMA) Webinar on Thursday, January 26th at 5 pm Pacific, 8 pm Eastern.

Jan 18, 2023 04:21 pm ET

Wellbeing Digital Announces Change of Auditor

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, today announces that is has changed its auditors. At the request of the Company, Macias Gini & O’Connell LLP (“Former Auditor”) resigned as the auditor of the company and the board of directors of the Company appointed Mao & Ying LLP (“Successor Audi

Dec 22, 2022 04:15 pm ET

Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has received a No Objection letter from Health Canada, on behalf of client Nova Mentis Life Science Corp. (“Nova Mentis” or the “Client”) (CSE:NOVA, OTC

Dec 08, 2022 08:10 am ET

Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), has been awarded an institution wide cannabis research license (the “Research License”) for their new state-of-the-art facility by Health Canada under the Can

Dec 06, 2022 07:30 am ET

Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that a clinical study conducted by its wholly owned subsidiary KGK Science Inc. (“KGK”), has shown positive results of UP446 supplementation in helping mount a robust immune response following influenza vaccination.

Nov 30, 2022 08:30 am ET

Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has submitted a clinical trial application (“CTA”) on behalf of client Nova Mentis Life Science Corp. (“Nova Mentis” or the “Client”) (CSE:NOVA, OTC:

Nov 29, 2022 07:30 am ET

Wellbeing Subsidiary Mindscape Treats its 1,000th Patient

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary Mindscape Ketamine & Infusion Therapy, PLLC (“Mindscape” or the “Clinic”), has treated its 1,000th patient with IV Ketamine Therapy for treatment-resistant mood disorders, mental health disorders

Nov 22, 2022 05:17 pm ET

Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces the appointment of Mohammad Sharifi to the Wellbeing Board of Directors (“the Board”), effective November 22, 2022. Mr. Mohammad Sharifi will serve as a member of the Audit Committee and Governance Committee of the Board.

Nov 18, 2022 04:30 pm ET

Wellbeing Digital Announces Resignation of Directors

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company.

Nov 17, 2022 08:30 am ET

Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Science Inc. (“KGK”), has entered into a research services agreement with Nova Mentis Life Science Corp. (“Nova Mentis”) (CSE:NOVA, OTC:NMLSF, FRA:HN3Q).

Nov 14, 2022 07:30 am ET

Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed an open label study, where Gefion Canada (“Gefion”) GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volun

Nov 02, 2022 07:30 am ET

Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Andrew Charrette, Director - Regulatory Affairs of KGK Sciences Inc. (“KGK”), the Company’s wholly owned subsidiary, will participate at this year's Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana

Oct 27, 2022 07:30 am ET

Wellbeing Announces Definitive Agreement to Divest IRP Health

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that it has entered into a definitive agreement (“Agreement”) under which Pathway Health Corp. (“Pathway”) will acquire all or substantially all of the operating assets of Wellbeing’s subsidiary IRP Health Ltd. (“IRP”).

Oct 25, 2022 07:30 am ET

Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana Wynwood Convention Centre.

Oct 13, 2022 07:30 am ET

Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Erin Lewis, Scientific Director of KGK Sciences Inc. (“KGK”), the Company’s wholly owned subsidiary, will participate at the Supply Side West Conference taking place on October 31st to November 4, 2022 in Las Vegas, NV.

Oct 11, 2022 07:30 am ET

Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, together with its wholly owned subsidiary KGK Sciences Inc. (“KGK”), applauds the efforts on the part of the Alberta Government in laying out an initial regulatory plan to regulate the administration of psychedelic drugs in anticipation of this growi

Oct 06, 2022 07:55 am ET

Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), today announced that the Company has completed the CMC package to be used in support of a phase 2A microdose psilocybin fragile X syndrome clinical trial for its client Nova Mentis

Oct 04, 2022 07:30 am ET

Wellbeing Digital Signs LOI Manage Additional Clinics

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that it has entered into an agreement to manage three additional clinics and accelerate the clinics growth efforts. Through this agreement, formalized with a Signed Letter of Intent (“LOI”), Wellbeing will be rolling in 3

Sep 29, 2022 07:30 am ET

Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate in the Cantor Fitzgerald Mental Health Clinics Symposium to be held virtually on October 11, 2022 at 9:00 a.m. ET.

Sep 26, 2022 07:30 am ET

Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”) has opened their new Clinical Research Center in London, Ontario, with the aim to accelerate their clients’ research and drug development needs in the nutraceutical, cannabinoid, he

Sep 23, 2022 07:30 am ET

Wellbeing Digital to Participate in the Microdose Psychedelic Capital Conference

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate in Microdose’s Psychedelic Capital: September 2022 Conference to be held virtually on September 29, 2022 at 1:30 p.m. ET.

Sep 15, 2022 07:49 am ET

Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that it has filed its financial results for the quarter ended July 31, 2022, the highlights of which are included in this news release. The full set of consolidated Financial Statement and Management Discussion and Analysis can be viewed by

Aug 30, 2022 07:30 am ET

Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, today announce the appointment of Najla Guthrie to the Benzinga Psychedelic Advisory Council.

Aug 25, 2022 07:30 am ET

Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo® Branded Ingredient from FDA

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”) provided regulatory guidance and expertise on behalf of its client, Hofseth Biocare ASA (HBC.OL) (“HBC” or the “Client”), to develop a New Dietary Ingredient (“NDI”) dossier for not

Aug 23, 2022 07:30 am ET

Wellbeing Subsidiary IRP Health Toronto Location Approved by Veterans Affairs Canada for Its Reactivation Program

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, pleased to announce that its subsidiary, IRP Health Ltd. (“IRP Health” or the “Subsidiary”), has received approval by Veterans Affairs Canada (“VAC”) for its multidisciplinary Reactivation-branded therapy program (“Reactivation”) at their new clinic

Aug 18, 2022 07:30 am ET

Wellbeing Corporate Update in a Letter from the CEO to its Shareholders

Aug 11, 2022 01:04 pm ET

Wellbeing Digital Sciences Inc. Changes Year-End

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) has filed the required notice to change its financial year end from July 31st to October 31st, in accordance with the requirements of National...

Jul 20, 2022 04:15 pm ET

Wellbeing Subsidiary KGK Science Enters Into Research Contract With Halucenex for Phase II Clinical Trial

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has entered into a research services agreement with Halucenex Life Sciences Inc. (“Halucenex”), a psychedelic subsidiary of Creso Pharma (ASX:CPH, OTC:COPHF, FRA:1X8).

Jun 21, 2022 07:30 am ET

Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations

Jun 17, 2022 07:30 am ET

Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive®) Supplementation in treating OA

Jun 16, 2022 06:44 pm ET

Wellbeing Digital Sciences Announces Q3 Financial Results and Provides Corporate Update

Jun 16, 2022 07:30 am ET

Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive®) Supplementation in treating OA

Jun 15, 2022 07:30 am ET

Wellbeing Digital Sciences Announces the Appointment of Terry Zimaro as Chief Financial Officer of the Company

Jun 09, 2022 07:30 am ET

Wellbeing subsidiary KGK Science and the International Probiotics Association (“IPA”) applauds FDA’s Commitment to Release NDI Draft Guidance Documents in the Near Future

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), subsidiary KGK Science Inc. applauds the efforts on the part of U.S. Food and Drug Administration (“FDA” or the “Agency”) to release the recent New...

Jun 01, 2022 05:00 pm ET

Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event

May 27, 2022 05:00 pm ET

Wellbeing Digital Sciences Announces Resignation of Chief Financial Officer

May 10, 2022 07:00 am ET

Wellbeing Digital Sciences Becomes a Founding Sponsor of the Women in Psychedelics Network

May 03, 2022 07:00 am ET

Wellbeing Digital Sciences Welcomes Dr. Michael Ho as New Medical Director of MindScape Clinic in Houston

Apr 28, 2022 07:00 am ET

Wellbeing Digital Sciences Subsidiary IRP Health Approved as Part of Coveted Chronic Pain Centre of Excellence for Canadian Veterans Network

Apr 25, 2022 07:00 am ET

Wellbeing Digital Sciences Forms Special Committee to Explore Advances in Digital Therapeutics for Mental Health

Apr 21, 2022 07:00 am ET

Wellbeing Digital Sciences Signs MOU with Pathway Health Regarding the Potential Sale of Certain Assets

Apr 19, 2022 10:01 am ET

Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science

Apr 14, 2022 07:00 am ET

Wellbeing Digital Sciences’ New CEO Unveils Evolved Competitive Strategy

Apr 04, 2022 07:00 am ET

Wellbeing Digital Sciences Welcomes Najla Guthrie as Chief Executive Officer

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract...

Mar 28, 2022 05:20 pm ET

Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation

Mar 22, 2022 07:00 am ET

Wellbeing Digital Sciences’ Subsidiary KGK Science Completes Clinical Study for Shakeology® that Validates Weight Loss Benefits

Mar 21, 2022 08:00 am ET

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

Mar 18, 2022 07:00 am ET

Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022

Mar 07, 2022 03:00 am ET

Wellbeing Digital Sciences Appoints Najla Guthrie as Chief Executive Officer

Mar 03, 2022 03:00 am ET

Wellbeing Digital Sciences Subsidiary IRP Health Receives Approval From Veterans Affairs Canada for Reactivation Program

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract...

Feb 15, 2022 03:00 am ET

Wellbeing Digital Sciences Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and...

Feb 02, 2022 03:00 am ET

Wellbeing Digital Sciences Reveals Recent Achievements by Its KGK Science Subsidiary

Jan 27, 2022 03:00 am ET

Wellbeing Digital Sciences’ Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and...

Jan 27, 2022 02:01 am ET

Nova Mentis and KGK Science Form Tactical Partnership

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada

Jan 24, 2022 03:00 am ET

Ketamine One Changes Name to Wellbeing Digital Sciences

Jan 17, 2022 03:00 am ET

Ketamine One Becomes Exclusive Ketamine Treatment Provider to Victoria Wellness

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce...

Jan 12, 2022 03:00 am ET

Ketamine One Begins Trading on the OTCQB Marketplace on January 12, 2022

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTCQB: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce...

Jan 10, 2022 03:00 am ET

Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event

Jan 05, 2022 03:00 am ET

Ketamine One Appoints Two New Members to Its Medical Advisory Board

Dec 20, 2021 11:11 am ET

Ketamine One Announces 2021 AGSM Results

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce the...

Dec 16, 2021 03:00 am ET

Ketamine One Reports Strong 1Q22 Financial Results

Dec 15, 2021 07:00 am ET

Ketamine One Announces Lifting of Management Cease Trade Order

Dec 14, 2021 05:00 pm ET

Ketamine One Appoints Joe Ramelli as Its New Chief Financial Officer

Dec 13, 2021 05:00 pm ET

Ketamine One Reports Audited Financial Results for the 2021 Fiscal Year

Dec 08, 2021 03:00 am ET

KetamineOne Adds Seattle Location to US Clinical Network

Dec 02, 2021 05:00 pm ET

KetamineOne Subsidiary KGK Science Helps Client Receive New Dietary Ingredient Status from U.S. FDA

Dec 02, 2021 08:30 am ET

Ketamine One Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it...

Nov 29, 2021 07:00 am ET

Ketamine One Provides Second Update on Management Cease Trade Order

Nov 16, 2021 03:00 am ET

Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce...

Nov 15, 2021 06:00 pm ET

Ketamine One Provides Update on Management Cease Trade Order

Nov 09, 2021 03:00 am ET

Ketamine One Announces Intention to Submit Draft Registration Statement for Proposed U.S. Initial Public Offering

Nov 04, 2021 06:00 pm ET

Ketamine One Announces Resignation of Loreto Grimaldi From Board of Directors

Nov 04, 2021 03:00 am ET

Ketamine One Announces Virtual Mental Healthcare Platform in Partnership With iHealthOX

Nov 01, 2021 07:04 pm ET

Ketamine One Announces Late Filing of Annual Financial Statements and Management Cease Trade Order

Oct 21, 2021 06:05 pm ET

Ketamine One Provides Updated Information for Stock Exchange Listings

Oct 20, 2021 03:00 am ET

Ketamine One Features Biostrap as Part of Inaugural Research Studies

Oct 14, 2021 03:00 am ET

Ketamine One Launching Two Inaugural Research Studies

Oct 12, 2021 08:30 am ET

Ehave Hires Contract Research Organization To Conduct Ketamine Clinical Trial In Miami, Florida

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by...

Oct 06, 2021 03:00 am ET

Ketamine One Subsidiary KGK Science Contracted to Support a Ketamine Clinical Trial in the United States

Sep 24, 2021 06:00 pm ET

Ketamine One Engages Integral Wealth as Its Market-Maker

Sep 21, 2021 07:00 am ET

Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center

Sep 14, 2021 07:00 am ET

Ketamine One Engages Psychology & Counselling Services Group for IRP Health

Sep 08, 2021 07:00 am ET

Ketamine One Signs LOI for Two Ketamine Infusion Clinics in Texas

Sep 01, 2021 07:00 am ET

Ketamine One to Deploy Cognetivity’s Integrated Cognitive Assessment Tool

Aug 30, 2021 07:00 am ET

Ketamine One Subsidiary IRP Health Expands With New Veteran-Focused Clinics

Aug 23, 2021 07:00 am ET

Ketamine One Establishes Medical Advisory Board

Aug 16, 2021 07:00 am ET

Ketamine One Subsidiary KGK Science Secures Multiple New Contracts

Aug 04, 2021 07:00 am ET

Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology

Jul 28, 2021 07:00 am ET

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Jul 22, 2021 07:00 am ET

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Jul 07, 2021 07:00 am ET

Ketamine One Announces Adam Deffett as Interim CEO

Jun 18, 2021 06:00 pm ET

Ketamine One Engages Various Providers of Investor Relations and Media Services

Jun 17, 2021 07:00 am ET

Ketamine One Highlights Psychedelic Research and Announces New Clinical Trial

Jun 15, 2021 06:00 pm ET

Ketamine One Closes Previously Announced Acquisition of Integrated Rehab and Performance

Jun 14, 2021 07:00 am ET

Ketamine One Appoints Loreto Grimaldi to Board of Directors

Jun 07, 2021 06:00 pm ET

Ketamine One Enters Into Arrangement Agreement to Transfer Investments

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that the Company has entered into...

Jun 07, 2021 06:00 am ET

Ketamine One Launches Immersive Virtual Reality R&D Program at MindScape Clinic

KetamineOne Capital Limited (formerly, Myconic Capital Corp.) ("Ketamine One" or the “Company”) (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce...

Jun 03, 2021 06:00 am ET

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Jun 01, 2021 06:00 am ET

Myconic Capital Becomes Ketamine One

Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (“Ketamine One” or the “Company”) from Myconic Capital Corp. and do business under the “Ketamine One” brand...

May 27, 2021 07:00 am ET

Auxly Reaches an Agreement With Myconic Capital to Sell KGK Science For Up to $16.5 Million in Value

Auxly Cannabis Group Inc. (TSX - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, announced today that it has entered into a definitive agreement with Myconic Capital Corp....

May 27, 2021 07:00 am ET

Myconic Capital to Acquire KGK Science From Auxly Cannabis Group

Myconic Capital Corp. (NEO: MEDI) (the “Company” or “Myconic”) is pleased to announce that the Company has entered into a definitive share purchase agreement (the “Agreement”), dated May 26, 2021, pursuant to which it will acquire 100% of each...

May 21, 2021 09:30 am ET

Myconic Capital Graduates Public Listing to the NEO Exchange

NEO is excited to announce that Vancouver-based Myconic Capital Corp. (“Myconic” or the “Company”), an in

May 18, 2021 05:00 pm ET

Myconic Capital Lists on the NEO Exchange

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (the "Company" or "Myconic") is pleased to announce that the Company has moved the listing of its common shares (the “Myconic Shares”) to the NEO Exchange (the “NEO”). The...

May 18, 2021 12:17 pm ET

CSE Bulletin: Delist - Myconic Capital Corp. (MEDI)

Toronto, Ontario--(Newsfile Corp. - le 18 mai/May 2021) - At the request of the company, the common shares of Myconic Capital Corp. (CSE: MEDI) will be delisted at market close on May 20, 2021.

May 10, 2021 07:52 am ET

Aleafia Health Completes Clinic Assets Transaction with Myconic Capital Corp.

Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that its wholly-owned subsidiaries, Canabo Medical Corporation (“Canabo”) and GrowWise Health Limited (“GrowWise”), (together the “Vendors”) have...

May 10, 2021 07:00 am ET

Myconic Capital Acquires Clinic Assets From Aleafia Health

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (the "Company" or "Myconic") is pleased to announce that the Company has executed and closed an asset purchase agreement (the “Purchase Agreement”) for the acquisition of...

Apr 23, 2021 08:00 am ET

Myconic Enters Into LOI to Acquire and Introduce Ketamine Treatments to Canada’s First and Only Multidisciplinary Physical Therapy Clinic Exclusively for Military, RCMP, and First Responder Patients

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Company” or “MEDI”) is pleased to announce that it has entered into a letter of intent (“LOI”) to acquire 100% of all issued and outstanding shares of...

Apr 21, 2021 08:56 pm ET

Myconic Capital Announces Closing of Mindscape Ketamine & Infusions Therapy Acquisition

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the "Company" or "Myconic") is pleased to announce that, further to its press release of March 10, 2021, it has completed the acquisition of all of the issued and...

Apr 20, 2021 08:00 am ET

Myconic Capital Corp. Enters Into Letter of Intent to Acquire a 49% Interest in Miami-Based Tristar Wellness LLC and Develop Satellite Ketamine Micro-Clinics

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Company” or “Myconic”) has entered into a letter of intent (“LOI”) with Tristar Wellness LLC (“Tristar”), operator of a wellness clinic in the Miami Beach...

Apr 07, 2021 08:00 am ET

Myconic Capital Appoints Adam Deffett as Vice President of Capital Markets

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (the "Company" or "Myconic") is pleased to announce that the Company has appointed Adam Deffett, CFA, as Vice President of Capital Markets & Communications. Mr. Deffett will...

Apr 05, 2021 08:00 am ET

Myconic Capital Corp. Signs Letter of Intent for Acquisition of NY Ketamine Medical Practice, PLLC

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Company” or “Myconic”) is pleased to announce that in its pursuit to establish an investment portfolio of leading ketamine treatment centers for depression and...

Mar 10, 2021 08:00 am ET

Myconic Capital Corp. Signs Letter of Intent for Acquisition of Mindscape Ketamine & Infusions Therapy, PLLC

Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the "Company" or "Myconic") is pleased to announce that the Company has entered into a letter of intent (the “LOI”) for the acquisition of all of the issued and...

Nov 12, 2020 03:18 pm ET

CSE Bulletin: New Listing - Myconic Capital Corp. (MEDI)

Toronto, Ontario--(Newsfile Corp. - Le 12 novembre/November 2020) - The common shares of Myconic Capital Corp. have been approved for listing on the CSE.

Ad blocking detected

Wellbeing Digital Sciences Inc. (E:MEDI)

Business Focus: Healthcare Facilities & Services (NEC)